Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review

Fiore, Marco; Maraolo, Alberto Enrico; Chiodini, Paolo; Cerchione, Claudio; Gentile, Ivan; Borgia, Guglielmo; Pace, Maria Caterina

doi:10.2174/1871529x17666170703115545

Cited by 5 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [51] Newer anticoagulants such as dabigatran and rivaroxaban require less monitoring and are said to have fewer drug interactions in those receiving therapy for TB or HIV. [54 , 55] Some studies have shown these agents to be efficacious and cost effective in developed countries. [56] There are a few studies analysing the cost effectiveness of these newer agents in public hospitals in developing countries.…”

Section: Discussionmentioning

confidence: 99%

Venous thromboembolic disease in adults admitted to hospital in a setting with a high burden of HIV and TB

Moodley

Martinson

Joyimbana

et al. 2021

Afr J Thorac Crit Care Med

View full text Add to dashboard Cite

Background. HIV and tuberculosis (TB) independently cause an increased risk for venous thromboembolic disease (VTE): deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Data from high HIV and TB burden settings describing VTE are scarce. The Wells' DVT and PE scores are widely used but their utility in these settings has not been reported on extensively. Objectives. To evaluate new onset VTE, compare clinical characteristics by HIV status, and the presence or absence of TB disease in our setting. We also calculate the Wells' score for all patients. Methods. A prospective cohort of adult in-patients with radiologically confirmed VTE were recruited into the study between September 2015 and May 2016. Demographics, presence of TB, HIV status, duration of treatment, CD4 count, viral load, VTE risk factors, and parameters to calculate the Wells' score were collected. Results. We recruited 100 patients. Most of the patients were HIV-infected (n=59), 39 had TB disease and 32 were HIV/TB co-infected. Most of the patients had DVT only (n=83); 11 had PE, and 6 had both DVT and PE. More than a third of patients on antiretroviral treatment (ART) (43%; n=18/42) were on treatment for <6 months. Half of the patients (51%; n=20/39) were on TB treatment for <1 month. The median (interquartile range (IQR)) DVT and PE Wells' score in all sub-groups was 3.0 (1.0 -4.0) and 3.0 (2.5 -4.5), respectively. Conclusion. HIV/TB co-infection appears to confer a risk for VTE, especially early after initiation of ART and/or TB treatment, and therefore requires careful monitoring for VTE and early initiation of thrombo-prophylaxis.

show abstract

Section: Discussionmentioning

confidence: 99%

Venous thromboembolic disease in adults admitted to hospital in a setting with a high burden of HIV and TB

Moodley

Martinson

Joyimbana

et al. 2021

Afr J Thorac Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Lind et al 8 "The aPTT does not correlate well with other tests that might be used to monitor parental DTI administration. "…”

Section: How Of Ten Are Parenter Al Anticoag Ul Ants Adminis Tered By...mentioning

confidence: 99%

“…Table 1 summarizes the errors that could be identified from this second search. In total, we identified 12 errors related to use of “parentally” administered “anticoagulants.” 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 Interestingly, the search string ((parenteral) AND (heparin OR anticoagulant OR enoxaparin OR clexane OR DTI OR “thrombin inhibitor” OR anticoagulant OR lepirudin OR argatroban OR bivalirudin)) only identified 2865 items, and so only around twice the number using “parental” instead of “parenteral” ( n = 1479).…”

Section: How Often Are Parenteral Anticoagulants Administered By Pare...mentioning

confidence: 99%

How often are parenteral anticoagulants administered by parents?

Favaloro

Pasalic

Lippi

2022

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Parenteral anticoagulants are a class of anticoagulants that need to be administered non‐orally, usually by injection or infusion. There are a variety of such agents, but heparin reflects the most frequently used. Being alerted to an error in a prior publication in which the word “parenteral” was inadvertently replaced by the word “parental,” it became clear that even experienced authors make such errors, which could then remain undetected by reviewers and editors, thus leading to failure in correction of same before publication. Given this is likely to be a somewhat ongoing error, we undertook a PubMed search of the literature to identify that “parentally administered” anticoagulants, as well as “parental” administration of other compounds, seems to be evident throughout the literature. We hope this report acts to raise awareness and help avoid similar errors in the future.

show abstract

“…DOACs could be an alternative for anticoagulation. However, data on their efficacy and safety in such cases are only a few [ 87 ].…”

Section: Tuberculosis and Vtementioning

confidence: 99%

Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns

Κεραμίδας

Gourgoulianis

Kotsiou

2021

JCM

View full text Add to dashboard Cite

Persistent inflammation within the respiratory tract underlies the pathogenesis of numerous chronic pulmonary diseases. There is evidence supporting that chronic lung diseases are associated with a higher risk of venous thromboembolism (VTE). However, the relationship between lung diseases and/or lung function with VTE is unclear. Understanding the role of chronic lung inflammation as a predisposing factor for VTE may help determine the optimal management and aid in the development of future preventative strategies. We aimed to provide an overview of the relationship between the most common chronic inflammatory lung diseases and VTE. Asthma, chronic obstructive pulmonary disease, interstitial lung diseases, or tuberculosis increase the VTE risk, especially pulmonary embolism (PE), compared to the general population. However, high suspicion is needed to diagnose a thrombotic event early as the clinical presentation inevitably overlaps with respiratory disorders. PE risk increases with disease severity and exacerbations. Hence, hospitalized patients should be considered for thromboprophylaxis administration. Conversely, all VTE patients should be asked for lung comorbidities before determining anticoagulant therapy duration, as those patients are at increased risk of recurrent PE episodes rather than DVT. Further research is needed to understand the underlying pathophysiology of in-situ thrombosis in those patients.

show abstract

Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review

Cited by 5 publications

References 26 publications

Venous thromboembolic disease in adults admitted to hospital in a setting with a high burden of HIV and TB

Venous thromboembolic disease in adults admitted to hospital in a setting with a high burden of HIV and TB

How often are parenteral anticoagulants administered by parents?

Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns

Contact Info

Product

Resources

About